BRIEF-Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus

Reuters06-17

June 17 (Reuters) - Marinus Pharmaceuticals Inc

* MARINUS PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 RAISE TRIAL OF IV GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS

* MARINUS PHARMACEUTICALS INC: RAISE TRIAL MET ITS FIRST CO-PRIMARY ENDPOINT

* MARINUS PHARMACEUTICALS INC: FAILED TO ACHIEVE STATISTICAL SIGNIFICANCE ON SECOND CO-PRIMARY ENDPOINT

* MARINUS PHASE 3 RAISE TRIAL MET FIRST ENDPOINT

* MARINUS EXPECTS PHASE 3 TRUSTTSC DATA IN Q4 2024

* MARINUS PHARMACEUTICALS INC: PROJECTS CASH RUNWAY INTO Q2 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444032168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-17 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444032168","market":"us","top_or_hot":-1,"title":"BRIEF-Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus","media":"Reuters","content":"<html><body><p>June 17 (Reuters) - <a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> Inc</p><p> :</p><p>   * MARINUS PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 RAISE TRIAL OF IV GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS</p><p>   * MARINUS PHARMACEUTICALS INC: RAISE TRIAL MET ITS FIRST CO-PRIMARY ENDPOINT</p><p>   * MARINUS PHARMACEUTICALS INC: FAILED TO ACHIEVE STATISTICAL SIGNIFICANCE ON SECOND CO-PRIMARY ENDPOINT</p><p>   * MARINUS PHASE 3 RAISE TRIAL MET FIRST ENDPOINT</p><p>   * MARINUS EXPECTS PHASE 3 TRUSTTSC DATA IN Q4 2024</p><p>   * MARINUS PHARMACEUTICALS INC: PROJECTS CASH RUNWAY INTO Q2 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 17 (Reuters) - Marinus Pharmaceuticals Inc :   * MARINUS PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 RAISE TRIAL OF IV GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS   * MARINUS ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNS","symbol_name":"Marinus Pharmaceuticals","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2444032168","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444032168","pubTimestamp":1718622619,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"June 17  - Marinus Pharmaceuticals Inc :   * MARINUS PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 RAISE TRIAL OF IV GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS   * MARINUS PHARMACEUTICALS INC: RAISE TRIAL MET ITS FIRST CO-PRIMARY ENDPOINT   * MARINUS PHARMACEUTICALS INC: FAILED TO ACHIEVE STATISTICAL SIGNIFICANCE ON SECOND CO-PRIMARY ENDPOINT   * MARINUS PHASE 3 RAISE TRIAL MET FIRST ENDPOINT   * MARINUS EXPECTS PHASE 3 TRUSTTSC DATA IN Q4 2024   * MARINUS PHARMACEUTICALS INC: PROJECTS CASH RUNWAY INTO Q2 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNS":"Marinus Pharmaceuticals","BK4007":"制药"},"translate_title":"BRIEF-Marinus Pharmaceuticals宣布静脉注射加奈索酮治疗难治性癫痫持续状态的3期RAISE试验的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNS":1},"content_text":"June 17 (Reuters) - Marinus Pharmaceuticals Inc :   * MARINUS PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 RAISE TRIAL OF IV GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS   * MARINUS PHARMACEUTICALS INC: RAISE TRIAL MET ITS FIRST CO-PRIMARY ENDPOINT   * MARINUS PHARMACEUTICALS INC: FAILED TO ACHIEVE STATISTICAL SIGNIFICANCE ON SECOND CO-PRIMARY ENDPOINT   * MARINUS PHASE 3 RAISE TRIAL MET FIRST ENDPOINT   * MARINUS EXPECTS PHASE 3 TRUSTTSC DATA IN Q4 2024   * MARINUS PHARMACEUTICALS INC: PROJECTS CASH RUNWAY INTO Q2 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444032168"}